Cochlear donates $10m to Johns Hopkins for new hearing loss center, research

March 2, 2018 By Fink Densford Leave a Comment

Cochlear Ltd. (ASX:COH) said today it donated $10 million to the Johns Hopkins Bloomberg School of Public Health to found the Cochlear Center for Hearing and Public Health, which it touted as the first academic institute looking to address hearing loss as a global health priority.

The new center is slated to be led by Dr. Frank Lin, and aims to conduct research to determine the effects of hearing loss on public health on a global scale. The center will also develop and test interventions looking to reduce the effects of hearing loss and create policies and strategies to improve hearing loss interventions, Cochlear said.

“The Cochlear Center for Hearing and Public Health will be dedicated to understanding and addressing the impact of hearing loss on public health. The center represents a unique collaboration between industry and academia that is possible because of the shared vision that hearing and our ability to engage effectively with others and the environment is fundamental to human health but not yet a priority in public health. Implementation of public health initiatives around hearing—or nearly any other public health problem—requires insights from industry into how to create scalable commercial and economic models for the development and delivery of services and technology. Cochlear will be able to provide these insights to the Center,” Dr. Lin said in a prepared release.

The $10 million gift will be delivered over 10 years, during which Cochlear will collaboarte with the center to help promote it and identify collaborative opportunities.

“At Cochlear, we are driven by our mission to improve the lives of people with hearing loss, and our gift to the Johns Hopkins Bloomberg School of Public Health supports this commitment. Hearing loss is a major public health problem. There is increasing evidence of the importance of hearing to overall health, especially as people age. Developing evidence of the impact of untreated hearing loss on people’s health, on our communities and the economy is critical to ensuring hearing loss is treated appropriately. Cochlear is making an investment to build collaborative partnerships within the global medical research community and to be actively involved in delivering evidence-based research so we can better understand, address and provide access to treatment options for individuals and communities impacted by hearing loss,” Cochlear prez & CEO Dig Howitt said in a prepared statement.

“This gift is a tribute to the accomplishments Johns Hopkins University has already achieved in our field and showcases our belief in the future achievements of the Center. It is also a reflection of our shared vision to make hearing and the ability to communicate priorities in the spheres of public health and policy. Through our work together, we hope hearing loss will no longer be an unaddressed, debilitating public health issue impacting the ability for so many to connect with others and to live full lives,” Cochlear chief medical officer Dr. David Cade said in a press release.

Last November, the FDA approved remote programming adjustments for Cochlear’s Nucleus cochlear implant, removing the need for a select group of users to make repeat visits for in-person programming sessions.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston

At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.

Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.

REGISTER NOW

FDA panel: Neuronix Alzheimer’s therapy fails to prove efficacy
An FDA advisory panel has recommended against granting de novo clearance to Neuronix’s NeuroAD system intended to slow the progress of mild to moderate Alzheimer’s disease. NeuroAD is approved for use in Europe, Australia and Israel, but the panel found that while it met FDA safety standards, clinical studies did not prove that it is… […]
Instron launches biomedical testing online training course
Instron (Norwood, Mass.) recently announced that it is foddering an online training program, “The Essentials of Biomedical Testing.” The course is designed to give an introduction and foundation to biomedical testing. It is an hour long course geared toward lab managers and test machine operators who work in the biomedical industry as well as test… […]
Linak touts new touch screen control for hospital beds
Linak has launched a new touch screen control for advanced hospital bets. The new touch screen is a large screen for the ACT controller to give users a view of all functions through an easy-to-use format. The controller also offers three levels of operation, which includes care mode for patients and relatives, extended care… […]
Myomo inks Italian sales deal
Myomo recently announced that it has signed a sales and service agreement with Progettiamo Autonomia Robotics (PAR) to market the MyoPro in Italy. Myomo is a wearable medical robotics company that gives functionality to people who have neurological disorders and upper limb paralysis. PAR is also focused on neurological pathologies and delivering devices for orthopedic… […]
Artificial intelligence and medicine: Is it overhyped?
Artificial intelligence raises exciting possibilities for healthcare, but are companies promising more than they can deliver? AI could possibly fuel the future of medtech, enabling such thrilling innovations as implanted devices that instantly react to minute changes, software that can identify the best treatment options for individuals facing life-threatening conditions and fully-functioning autonomous surgical systems.… […]
ACell signs South Korean distribution agreement
ACell (Columbia, Md.) announced that it has signed an exclusive distribution agreement with MyungMoon Bio to market ACell’s wound matrix devices in South Korea. “South Korea is one of the largest healthcare markets in the Asia Pacific, and this agreement will meet a growing unmet need for innovative wound management solutions in the country,” Nino… […]
VisionCare wins approval for CentraSight implant in Australia
VisionCare (Saratoga, Calif.) recently announced that it has received regulatory approval from the Australian Department of Health Therapeutic Goods Administration for its Implantable Miniature Telescope. The miniature telescope is designed to improve the visual acuity in patients who are 55 years or older and have bilateral moderate to profound central vision impairment because of age-related… […]
Millstone Medical appoints new EVP of sales and business development
Millstone Medical announced that it has appointed Richard Worthen as its executive VP of sales and business development at its Massachusetts headquarters. Prior to joining Millstone Medical, Worthen served as VP of North American sales at Clozex Medical where he helped launch the company’s Class I skin closure device. He has also held a number… […]
SMC expands Wisconsin facility capabilities
SMC recently announced that it is expanding is drug delivery device capabilities by adding a pharmaceutical class 7 cleanroom at its Somerset, Wisc. facility. “As we continue to experience growth in the pharmaceutical market, we realized the need for additional clean room capabilities in our Somerset, Wisc. location,” Chetan Patel, CEO of SMC, said. “The… […]
March 2019 Issue: Can AI truly transform medicine?
Medtech is going digital: So how do we keep it real? One of medtech veteran Mir Imran’s biggest claims to fame is that, as a young engineer in the early 1980s, he played a pivotal role in the development of the first implantable ICD. Imran told me a startling fact a few years ago: FDA… […]
NE Ohio biomedical industry investments on the rise
Investment in the northeast Ohio biomedical sector totaled nearly $294 million in 2018 with 71 regional companies receiving funding, according to regional healthcare trade group BioEnterprise. Those figures make this region the third largest for total healthcare investment in the Midwest, following Minneapolis ($664 million) and Chicago ($551 million). These were among the findings of… […]